Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000099.xml
Z Orthop Unfall 2023; 161(02): 175-181
DOI: 10.1055/a-1488-6912
DOI: 10.1055/a-1488-6912
Review/Übersicht
Drug-induced Myopathies
Article in several languages: English | deutsch
Abstract
Differential diagnosis of muscle pain and weakness is extensive, including neurological, vertebral, arthrogenic, vascular, traumatic, immunological, endocrine, genetic and infectious aetiologies, as well as medication or toxin-related causes. Muscles are highly sensitive to a large number of drugs, especially with high doses. Although many drug classes can cause toxic myopathy, a significant number of cases are caused by lipid-lowering drugs, long-term use of corticosteroids, and, most often, alcohol misuse. Some drug interactions, e.g. those that are metabolised via the enzyme CYP3A4, can increase the serum levels of the drugs and drug-induced toxicity. A careful history of patientʼs drug and alcohol consumption is therefore vital. Clinical symptoms depend on the drug, dosage and patientʼs sensitivity. They can vary from asymptomatic increase in serum levels of creatine kinase, mild myalgia and cramps to muscle weakness, rhabdomyolysis, kidney failure and even death. The pathogenesis is often only partially known and multifactorial. Toxic myopathy is often reversible once the drug is discontinued, alternative drug therapy is started or a different dosage regimen is chosen. Complications such as acute kidney failure must be avoided, and analgesic therapy may be indicated.
Publication History
Article published online:
28 July 2021
© 2021. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References/Literatur
- 1 Heuß D. et al. Diagnostik und Differenzialdiagnose bei Myalgien, S1-Leitlinie. Im Internet (Stand: 08.02.2021): https://dgn.org/wp-content/uploads/2013/01/030051_LL_Myalgien_2020.pdf
- 2 Deutsche Schmerzgesellschaft. Hrsg. Definition, Pathophysiologie, Diagnostik und Therapie des Fibromyalgiesyndroms. Im Internet (Stand: 08.02.2021): https://www.awmf.org/uploads/tx_szleitlinien/145-004l_S3_Fibromyalgiesyndrom_2019-11_1.pdf
- 3 Deschauer M. et al. S1-Leitlinie Diagnostik von Myopathien. Im Internet (Stand: 08.02.2021): https://dgn.org/wp-content/uploads/2013/01/030115_LL_Diagnostik_von_Myopathien_2016_verlaengert.pdf
- 4 Dalakas MC. Toxic and drug-induced myopathies. J Neurol Neurosurg Psychiatry 2009; 80: 832-838 DOI: 10.1136/jnnp.2008.168294.
- 5 Walsh RJ, Amato AA. Toxic myopathies. Neurol Clin 2005; 23: 397-428 DOI: 10.1016/j.ncl.2004.12.014.
- 6 Preedy VR, Ohlendieck K, Adachi J. et al. The importance of alcohol-induced muscle disease. J Muscle Res Cell Motil 2003; 24: 55-63 DOI: 10.1023/a:1024842817060.
- 7 Pasnoor M, Barohn RJ, Dimachkie MM. Toxic myopathies. Curr Opin Neurol 2018; 31: 575-582 DOI: 10.1097/WCO.0000000000000606.
- 8 Hough CL, Steinberg KP, Taylor Thompson B. et al. Intensive care unit-acquired neuromyopathy and corticosteroids in survivors of persistent ARDS. Intensive Care Med 2009; 35: 63-68 DOI: 10.1007/s00134-008-1304-4.
- 9 Barohn RJ, Gajewski B, Pasnoor M. et al. Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS): Bayesian Adaptive Comparative Effectiveness Randomized Trial. JAMA Neurol 2020; DOI: 10.1001/jamaneurol.2020.2590.
- 10 Klose G, Schwabe U. Lipidsenkende Mittel. In: Schwabe U, Ludwig W-D. Hrsg. Arzneiverordnungs-Report 2020. Berlin, Heidelberg: Springer; 2020: 601-614
- 11 Nguyen KA, Li L, Lu D. et al. A comprehensive review and meta-analysis of risk factors for statin-induced myopathy. Eur J Clin Pharmacol 2018; 74: 1099-1109 DOI: 10.1007/s00228-018-2482-9.
- 12 Turner RM, Radman I, Bozina N. et al. Pharmacogenetics and statin-related myopathy: what do we know?. Pharmacogenomics 2020; 21: 821-825 DOI: 10.2217/pgs-2020-0041.
- 13 Turner RM, Pirmohamed M. Statin-Related Myotoxicity: A Comprehensive Review of Pharmacokinetic, Pharmacogenomic and Muscle Components. J Clin Med 2019; 9: 22 DOI: 10.3390/jcm9010022.
- 14 Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med 2012; 125: 882-887.e1 DOI: 10.1016/j.amjmed.2011.12.013.
- 15 Hansen KE, Hildebrand JP, Ferguson EE. et al. Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med 2005; 165: 2671-2676 DOI: 10.1001/archinte.165.22.2671.
- 16 Collins R, Reith C, Emberson J. et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 2016; 388: 2532-2561 DOI: 10.1016/S0140-6736(16)31357-5.
- 17 Grundy SM, Stone NJ, Bailey AL. et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019; 139: e1046-e1081 DOI: 10.1161/CIR.0000000000000624.
- 18 Stroes ES, Thompson PD, Corsini A. et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J 2015; 36: 1012-1022 DOI: 10.1093/eurheartj/ehv043.
- 19 Mach F, Baigent C, Catapano AL. et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41: 111-188 DOI: 10.1093/eurheartj/ehz455.
- 20 Gupta A, Thompson D, Whitehouse A. et al. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. Lancet 2017; 389: 2473-2481 DOI: 10.1016/S0140-6736(17)31075-9.
- 21 Wood FA, Howard JP, Finegold JA. et al. N-of-1 Trial of a Statin, Placebo, or No Treatment to Assess Side Effects. N Engl J Med 2020; 383: 2182-2184 DOI: 10.1056/NEJMc2031173.
- 22 Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003; 289: 1681-1690 DOI: 10.1001/jama.289.13.1681.
- 23 Laufs U, Scharnagl H, Halle M. et al. Treatment Options for Statin-Associated Muscle Symptoms. Dtsch Arztebl Int 2015; 112: 748-755 DOI: 10.3238/arztebl.2015.0748.
- 24 Gheorghe G, Toth PP, Bungau S. et al. Cardiovascular Risk and Statin Therapy Considerations in Women. Diagnostics (Basel) 2020; 10: 483 DOI: 10.3390/diagnostics10070483.
- 25 Barry AR, Beach JE, Pearson GJ. Prevention and management of statin adverse effects: A practical approach for pharmacists. Can Pharm J (Ott) 2018; 151: 179-188 DOI: 10.1177/1715163518768534.
- 26 Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006; 97: 52C-60C DOI: 10.1016/j.amjcard.2005.12.010.
- 27 Bouitbir J, Sanvee GM, Panajatovic MV. et al. Mechanisms of statin-associated skeletal muscle-associated symptoms. Pharmacol Res 2020; 154: 104201 DOI: 10.1016/j.phrs.2019.03.010.
- 28 Hoppstädter J, Valbuena Perez JV, Linnenberger R. et al. The glucocorticoid-induced leucine zipper mediates statin-induced muscle damage. FASEB J 2020; 34: 4684-4701 DOI: 10.1096/fj.201902557RRR.
- 29 Draeger A, Monastyrskaya K, Mohaupt M. et al. Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia. J Pathol 2006; 210: 94-102 DOI: 10.1002/path.2018.
- 30 Elam MB, Majumdar G, Mozhui K. et al. Patients experiencing statin-induced myalgia exhibit a unique program of skeletal muscle gene expression following statin re-challenge. PLoS One 2017; 12: e0181308 DOI: 10.1371/journal.pone.0181308.
- 31 Kuhm C, Klopstock T. Toxische Myopathien. Arzneimitteltherapie 2014; 32: 87-92
- 32 Sparing R, Sellhaus B, Noth J. et al. Rhabdomyolyse unter Cerivastatin-Monotherapie. Konsequenzen für die Therapie mit HMG-CoA-Reduktase-Hemmern?. Nervenarzt 2003; 74: 167-171 DOI: 10.1007/s00115-002-1441-x.
- 33 Hussain Y, Miller S. Other Myopathies. Neurol Clin 2020; 38: 619-635 DOI: 10.1016/j.ncl.2020.04.002.
- 34 Dimachkie MM, Barohn RJ, Amato AA. Idiopathic inflammatory myopathies. Neurol Clin 2014; 32: 595-628 vii DOI: 10.1016/j.ncl.2014.04.007.
- 35 Mor A, Wortmann RL, Mitnick HJ. et al. Drugs causing muscle disease. Rheum Dis Clin North Am 2011; 37: 219-231 vi DOI: 10.1016/j.rdc.2011.01.005.
- 36 Deutsche Gesellschaft für Kardiologie – Herz- und Kreislaufforschung e. V.. ESC/EAS Pocket Guidelines. Diagnostik und Therapie der Dyslipidämien (Version 2019). Im Internet (Stand: 18.11.2020): https://leitlinien.dgk.org/2020/pocket-leitlinie-diagnostik-und-therapie-der-dyslipidaemien-version-2019/
- 37 Pasnoor M, Barohn RJ, Dimachkie MM. Toxic myopathies. Neurol Clin 2014; 32: 647-670 viii DOI: 10.1016/j.ncl.2014.04.009.
- 38 Katzberg HD, Kassardjian CD. Toxic and Endocrine Myopathies. Continuum (Minneap Minn) 2016; 22: 1815-1828 DOI: 10.1212/CON.0000000000000407.
- 39 Bowyer SL, LaMothe MP, Hollister JR. Steroid myopathy: incidence and detection in a population with asthma. J Allergy Clin Immunol 1985; 76: 234-242 DOI: 10.1016/0091-6749(85)90708-0.
- 40 Latronico N, Tomelleri G, Filosto M. Critical illness myopathy. Curr Opin Rheumatol 2012; 24: 616-622 DOI: 10.1097/BOR.0b013e3283588d2f.
- 41 Kuncl RW, Duncan G, Watson D. et al. Colchicine myopathy and neuropathy. N Engl J Med 1987; 316: 1562-1568 DOI: 10.1056/NEJM198706183162502.
- 42 Wilbur K, Makowsky M. Colchicine myotoxicity: case reports and literature review. Pharmacotherapy 2004; 24: 1784-1792 DOI: 10.1592/phco.24.17.1784.52334.
- 43 Teener JW. Inflammatory and toxic myopathy. Semin Neurol 2012; 32: 491-499 DOI: 10.1055/s-0033-1334467.
- 44 Baker SK, Goodwin S, Sur M. et al. Cytoskeletal myotoxicity from simvastatin and colchicine. Muscle Nerve 2004; 30: 799-802 DOI: 10.1002/mus.20135.
- 45 McKinnell J, Tayek JA. Short term treatment with clarithromycin resulting in colchicine-induced rhabdomyolysis. J Clin Rheumatol 2009; 15: 303-305 DOI: 10.1097/RHU.0b013e3181bbbcd7.
- 46 Faucheux JM, Tournebize P, Viguier A. et al. Neuromyopathy secondary to omeprazole treatment. Muscle Nerve 1998; 21: 261-262 DOI: 10.1002/(sici)1097-4598(199802)21:2<261::aid-mus21>3.0.co;2-3.
- 47 Clark DWJ, Strandell J. Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors?. Eur J Clin Pharmacol 2006; 62: 473-479 DOI: 10.1007/s00228-006-0131-1.
- 48 Hogan Q, Dotson R, Erickson S. et al. Local anesthetic myotoxicity: a case and review. Anesthesiology 1994; 80: 942-947 DOI: 10.1097/00000542-199404000-00029.
- 49 Babhulkar SS. Triceps contracture caused by injections. A report of 11 cases. J Bone Joint Surg Br 1985; 67: 94-96 DOI: 10.1302/0301-620X.67B1.3968153.
- 50 Burnei G, Neagoe P, Margineanu BA. et al. Treatment of severe iatrogenic quadriceps retraction in children. J Pediatr Orthop B 2004; 13: 254-258 DOI: 10.1097/01.bpb.0000111028.02081.2e.
- 51 Chen HC, Huang TF, Chou PH. et al. Deltoid contracture: a case with multiple muscle contractures. Arch Orthop Trauma Surg 2008; 128: 1239-1243 DOI: 10.1007/s00402-007-0479-4.